#USA #Lenexa #ELIAS Animal Health #ECI #canine cancer treatment

ELIAS Animal Health's ECI®: A Breakthrough in Canine Cancer Treatment

In a historic move for veterinary medicine, ELIAS Animal Health has announced the full approval of its pioneering treatment, the ELIAS Cancer Immunotherapy (ECI®), by the U.S. Department of Agriculture (USDA). This groundbreaking adoptive cell therapy becomes the first of its kind to receive such approval, specifically targeting canine osteosarcoma, a deadly form of bone cancer commonly found in large and giant dog breeds.

Understanding Canine Osteosarcoma

Bone cancer is one of the leading causes of death among dogs aged two and older, with approximately six million dogs diagnosed each year. Osteosarcoma is particularly aggressive, often affecting breeds such as Golden Retrievers, Boxers, and German Shepherds. The disease presents significant challenges for veterinary oncologists, highlighting the urgent need for innovative treatment options.

ELIAS Animal Health’s ECI® functions by utilizing the dog's own immune system to combat cancer. The therapy begins with conditioning the immune system to recognize the tumor as a target, followed by the administration of activated killer T cells. These cells are designed to seek out and destroy the malignant cells, offering a new avenue for treating this aggressive cancer.

ECI®: Availability and Treatment Protocol

Currently, ECI® is available at 100 authorized treatment centers across the United States, marking a significant milestone in the treatment of canine cancer. For veterinarians interested in offering this therapy, it is essential to collect cancerous tissue prior to any surgical intervention. This tissue is used to manufacture the personalized treatment, ensuring the highest chances of efficacy.

Tammie Wahaus, CEO of ELIAS Animal Health, expressed her excitement regarding the approval, stating, “The approval of ECI® marks a culmination of years of dedicated research and is aligned with our mission to improve animal health and the lives of pets.” This sentiment echoes throughout the veterinary community, as more clinicians gain access to advanced therapies that leverage the natural abilities of a pet’s immune system.

The Significance of Immunotherapy in Veterinary Medicine

Dr. Noe Reyes, Chief Medical Officer at ELIAS Animal Health, elaborated on the importance of immunotherapies like ECI®, saying, “Immunotherapies represent a transformative shift in our approach to cancer treatment, as we harness the power of the patient’s own biology to fight their disease.” This treatment not only provides hope for dogs suffering from osteosarcoma but also paves the way for future advancements in veterinary oncology.

Looking Ahead: The Future of Canine Cancer Treatment

As ELIAS Animal Health continues to innovate in the realm of canine cancer therapies, the company showcases its commitment to enhancing treatment options within the veterinary field. This approval underscores the potential for improved clinical outcomes and the prospect of radically changing the approach to cancer treatment in companion animals.

For pet owners and veterinarians alike, the introduction of ECI® signifies a leap forward in the fight against canine cancer, offering a new ray of hope for patients previously faced with limited treatment options.

For more information about ECI® and its availability, visit ELIAS Animal Health's website.

In conclusion, with the successful implementation of the ELIAS Cancer Immunotherapy, ELIAS Animal Health stands at the forefront of veterinary medicine, committed to pioneering advancements in cancer therapy tailored specifically for our beloved canine companions.